This announcement is a separate document:
自愿披露关于赛立奇单抗中重度斑块状银屑病适应症获批上市的公告
Voluntary disclosure announcement on approval for marketing of celizumab as an indication for moderate to severe plaque psoriasis
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.